Connect your AI

Vericel VCEL Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Zimmer Biomet HoldingsZBH

$12.3M-26.3%

LeMaitre VascularLMAT

$2.95M+125%

EnovisENOV

$628K+84.2%

Capricor TherapeuticsCAPR

$1.47M+2,821%

Globus MedicalGMED

$25.96M+131%

Other financials

Income statement

Revenue$68.4M+30.1%

Gross profit$49.3M+35.8%

Operating income-$8.1M+37.0%

Net income-$6.3M+44.0%

EPS (diluted)-$0.12+47.8%

Balance sheet

Cash & equivalents$109.3M+37.1%

Total debt$95.0M-4.6%

Total equity$356.2M+20.6%

Total assets$485.6M+14.4%

Cash flow

Operating cash flow$16.4M+148%

CapEx$1.3M-91.2%

Free cash flow$15.1M+299%

Valuation

Market cap$2.13B-26.8%

Profitability

Gross margin74.8%+2.3pp

Operating margin5.4%+4.6pp

Net margin7.3%+6.1pp

FCF margin16.3%—

Returns & leverage

Return on equity6.6%+5.5pp

Debt / equity0.3×-0.1×

Current ratio5.2×+0.2×

Where this comes from

Reported directly by Vericel in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Vericel’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vericel's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Vericel's stock issuance proceeds?: Vericel (VCEL) reported stock issuance proceeds of $1.56M in Q1 2026.
How has Vericel's stock issuance proceeds changed year-over-year?: Vericel's stock issuance proceeds decreased by 83.4% year-over-year, from $9.41M to $1.56M.
What is the long-term trend for Vericel's stock issuance proceeds?: Over 4 years (2021 to 2025), Vericel's stock issuance proceeds has grown at a 5.7% compound annual growth rate (CAGR), from $11.18M to $13.93M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.